GENERAL29 Sept 2026
US pharma tariffs widen today, with zero duty for select Indian medicines
From today, the US is widening its pharma tariffs, charging 100 percent on more companies. But India is one of 20 jurisdictions getting zero duty on specified speciality medicines. Generic drugs stay outside these Section 232 tariffs. Relief covers only the listed categories, so exporters of other medicines face the higher duty. Check whether your product is on the zero-duty list before planning shipments.
Key Statutory Highlights
- India is one of 20 jurisdictions eligible for zero US tariffs on specified speciality medicines.
- Generic drugs remain outside the scope of the US Section 232 pharmaceutical tariffs.
- The US is extending its 100 percent pharma tariff to more companies, and the relief applies only to the listed categories.
Actionable Advice for Taxpayers / Founders:If you export medicines to the US, check whether your product falls within the listed speciality categories that qualify for zero duty, and confirm the current position with your customs adviser before you plan shipments.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: